Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867260 | 0.89 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3R1SMN1; SMN2USP2 | |
| SCHEMBL993496 | 0.81 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL994312 | 0.81 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL1870405 | 0.81 | SMN1; SMN2 (0.47) | PIK3CDPIK3CAPIK3R1SMN1; SMN2PIK3CB | |
| SCHEMBL994008 | 0.81 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG | |
| SCHEMBL4438796 | 0.81 | SMN1; SMN2 (0.50) | PIK3CDPIK3CAPIK3R1SMN1; SMN2PIK3CB | |
| SCHEMBL466290 | 0.80 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3R1PIK3CBMTOR | |
| SCHEMBL1865963 | 0.79 | PIK3CA (0.42) | PIK3CDPIK3CAPIK3R1SMN1; SMN2USP2 | |
| SCHEMBL2672415 | 0.79 | PIK3CD (0.43) | PIK3CDPIK3CAPIK3R1SMN1; SMN2USP2 | |
| SCHEMBL994383 | 0.79 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3R1PIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | PIK3CD 10/4885PIK3CA 6/4885PIK3R1 25/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | PIK3CD 5/4885PIK3CA 1/4885PIK3R1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.